In November 2020, Cronos GrowCo obtained a cultivation license for the operations contemplated by the first phase of the project. Cronos Group Inc. shares slid 2.4% Friday, after the Canadian cannabis company posted a wider-than-expected loss for the fourth quarter, but revenue that beat estimates, buoyed by … Cronos, which belongs to the Zacks Medical - Drugs industry, posted revenues of $11.36 million for the quarter ended September 2020, surpassing the Zacks Consensus Estimate by … Offset by third party purchased flower associated with adult-use products in Canada and a decline in wholesale sales in Q4 2020 versus Q4 2019. Management uses Adjusted EBITDA by segment for planning, forecasting and evaluating business and financial performance, including allocating resources and evaluating results relative to employee compensation targets. The increase year-over-year was primarily driven by spending at the Company’s Peace Naturals campus, Cronos Fermentation, our Israeli facility, and our new ERP system. Management did not view the income and expense items above to be part of underlying results of the segment as they may have been highly variable, unusual or infrequent, were difficult to predict and could distort underlying business trends and results. Instructions for the conference call are provided below: Cronos Group is an innovative global cannabinoid company with international production and distribution across five continents. As a result of the appointment of Mr. Schmidt as President and Chief Executive Officer in September 2020 and a review of how management looks at the business, adjusted operating loss is no longer a primary metric upon which management views the consolidated business performance and results year-over-year. The Company will host a conference call and live audio webcast on Friday, February 26, 2021 at 8:30 a.m. EST to discuss 2020 fourth quarter and full-year business results and outlook. On January 11, 2021, the PEACE NATURALS™ brand was recognized by the Israeli Marketing Association and was given the 2020 Innovation Award for its successful marketing strategy in 2020, which led to increased brand exposure. Cronos Group ebitda from 2017 to 2020. The Company’s method of allocating corporate expenses is refined periodically. For FY 2020, the Company reported a gain on revaluation of derivative liabilities of $129.3 million representing a decrease of $1,147.6 million from FY 2019 primarily driven by a decrease in the Company's share price since December 31, 2019. Cronos delivered net revenue increased 133% to $17.0 million in the fourth quarter versus $9.7 million for the same time period in 2019. For further information, see Note 14 to the consolidated financial statements in Item 8 of the Company’s Annual Report on Form 10-K. Impairment loss on goodwill and intangible assets. These financial statement review costs include costs related to the restatement of the Company’s 2019 interim financial statements, costs related to the Company’s responses to requests for information from various regulatory authorities relating to such restatement and legal costs defending shareholder class action complaints brought against the Company as a result of the restatement. As used in this press release, “CBD” means cannabidiol and “U.S. Cronos Group’s Rest of World reporting segment includes results of the Company’s operations for all markets outside of the U.S. Cronos Group’s U.S. reporting segment includes results of the Company’s operations for all brands and products in the U.S. Cronos Group Reports 2020 Fourth Quarter and Full-Year Results . The exchange rates used to translate from USD to Canadian dollars (“C$”) is shown below: For further information, please contact: Shayne Laidlaw Investor Relations Tel: (416) 504-0004 [email protected], Cronos Group Reports 2020 Fourth Quarter and Full-Year Results. Net revenue was $2.2 million in Q1 2020, of which the primary contributors to revenue in the quarter were the continued distribution of products in both e-commerce and physical retail channels and the introduction of Lord Jones™ Acid Mantle Repair CBD Moisturizer. Corporate expenses are expenses that relate to the consolidated business. Rather, these non-GAAP measures are provided as a supplement to corresponding US GAAP measures to provide additional information regarding our results of operations from management’s perspective. The Company incurred an inventory write-down in Q4 2020 of $15.0 million, on dried cannabis and cannabis extracts, primarily driven by cannabis product price compression in the Canadian market. The Company may incur further inventory write-downs due to pricing pressures in the marketplace. Cronos (CRON) delivered earnings and revenue surprises of -216.67% and 16.96%, respectively, for the quarter ended June 2020. For further information, see Note 27 and Note 14 to the consolidated financial statements in Item 8 of the Company's Annual Report on Form 10-K. For Q4 2020, the Company reported no financing and transaction costs representing a decrease of $0.5 million from Q4 2019. The call will last approximately one hour. The assets and liabilities of the Company’s foreign operations are translated into dollars at the exchange rate in effect as of December 31, 2020, December 31, 2019 and December 31, 2018 as reported on Bloomberg. The NCV Newswire by New Cannabis Ventures aims to curate high quality content and information about leading cannabis companies to help our readers filter out the noise and to stay on top of the most important cannabis business news. The decrease year-over-year was primarily driven by a reduction in spending at the Company’s Peace Naturals campus and Cronos Israel. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the Forward-Looking Statements in this press release and other reports we file with, or furnish to, the SEC and other regulatory agencies and made by our directors, officers, other employees and other persons authorized to speak on our behalf. Adjusted EBITDA loss of $147.3 million in Full-Year 2020 increased by $48.9 million from Full-Year 2019. In 2020, Cronos generated $46.7 million in revenue. This is a list of the world's largest cannabis companies by revenue.The list shows cannabis companies ranked by annual revenue. The call will last approximately one hour. The company has topped consensus revenue estimates just once over the last four quarters. The Chicago-based cannabis company reported a fourth quarter revenue increase of 12.8% as of Dec. 31, 2020, and a 133.8% year-over-year revenue increase to $177.2 million. Net revenue of $37.2 million in Full-Year 2020 increased by $16.8 million from Full-Year 2019. Canadians purchased CA$109 million worth of recreational cannabis edibles in 2020. There were no repurposing costs incurred during FY 2020. On September 9, 2020, Cronos Group expanded its leadership structure to drive its next phase of growth by appointing Kurt Schmidt as President and Chief Executive Officer. Corporate expenses are removed from Adjusted EBITDA by segment. The Company will host a conference call and live audio webcast on Friday, February 26, 2021 at 8:30 a.m. EST to discuss 2020 fourth quarter and full-year business results and outlook. Corporate expenses are removed from Adjusted EBITDA by segment. The company reported consolidated net revenue in the first quarter of 2021 of $12.6 million, a 50% increase from the prior-year period. The Company expects continued changes in derivative valuations as the Company’s share price fluctuates period-to-period. TORONTO, Feb. 26, 2021 (GLOBE NEWSWIRE) — Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos Group” or the “Company”), today announces its 2020 fourth quarter and full-year business results. For further information, see Note 14 to the consolidated financial statements in Item 8 of the Company’s Annual Report on Form 10-K. For Q4 2020, the Company reported a loss on revaluation of derivative liabilities of $53.5 million representing a decrease of $172.4 million from Q4 2019 primarily driven by a decrease in the Company’s share price since December 31, 2019. The increase in losses year-over-year was primarily driven by an increase in general and administrative expenses and an increase in R&D spending. As we look to 2021, I’m incredibly excited about the teams we have supporting our brands and the breakthrough research and development ("R&D"), innovation and exciting marketing campaigns Cronos Group plans to execute on. Its … Investments in equity accounted investees, Total equity attributable to shareholders of, Share of loss from investments in equity accounted investees, Foreign exchange gain (loss) on translation, Gain on revaluation and disposal of other investments, net of tax, Gain (loss) on revaluation of derivative liabilities, Share of income (loss) from investments in equity accounted investees, Impairment on goodwill and intangible assets, Provisions for inventory and doubtful accounts, Other non-cash operating activity expense (income), Net cash provided by (used in) operating activities, Proceeds from (purchase of) short-term investments, net, Purchase of property, plant and equipment, net of disposals, Other non-cash investing activity expense (income), Net cash provided by (used in) investing activities, Proceeds from exercise of warrants and options, Net cash provided by (used in) financing activities, Effect of foreign currency translation on cash and cash equivalents, Cash and cash equivalents, beginning of period, Share of loss from equity accounted investees, Loss on revaluation of derivative liabilities, The Company incurred an inventory write-down in Q4 2020 of, The Company incurred an inventory write-down in Full-Year 2020 of. Management reviews Adjusted EBITDA, a non-GAAP measure which excludes non-cash items or items that do not reflect management’s assessment of on-going business performance. The full collection of Happy Dance™ products is expected to launch online at ULTA.com and in-store in over 550 ULTA Beauty™ locations across the U.S. in the coming weeks. Cronos Group is committed to building disruptive intellectual property by advancing cannabis research, technology and product development. Analysts expect Cronos Group to report revenues of 13 million Canadian dollars—a growth of 103.1% YoY (year-over-year). Net revenue of $46.7 million in Full-Year 2020 increased by $23.0 million from Full-Year 2019. For FY 2020, the Company reported a gain on disposal of other investments of $4.8 million representing a decrease of $11.5 million from FY 2019 primarily driven by a decrease in the sale of shares associated with the Whistler Transaction (as defined below) during FY 2020 compared to FY 2019. The Company anticipates that gross margin will continue to fluctuate as price and mix change from quarter-to-quarter. Due to the continued public health concerns related to … It also dropped sequentially from the fourth quarter’s consolidated net revenue of $17 million. Management believes that Adjusted EBITDA by segment provides useful insight into underlying segment trends and results and provides a more meaningful comparison of year-over-year segment results. Management used to use adjusted operating loss for planning, forecasting and evaluating business and financial performance, including allocating resources and evaluating results relative to employee compensation targets. Marijuana company Cronos Group Inc. (NASDAQ: CRON) on Thursday reported financial results for the third quarter of 2020. Cronos reported revenue in the first quarter of $12.6 million. The NCV Newswire is hand-curated by an editor and not automated in anyway. For Q4 2020, the Company reported interest income, net of $3.1 million, representing a decrease of $4.4 million from Q4 2019 primarily due to the impact of a decrease in interest rates on cash and cash equivalents and short-term investments during Q4 2020 compared to Q4 2019. Forward-Looking Statements are made as of the date they are made and are based on the beliefs, estimates, expectations and opinions of management on that date. Adjusted EBITDA loss of $11.8 million in Q4 2020 increased by $10.6 million from Q4 2019. The Company may incur further inventory write-downs due to pricing pressures in the marketplace. Capital expenditures of $35.4 million in Full-Year 2020 decreased by $3.6 million from Full-Year 2019. The improvement year-over-year was primarily driven by a decline in gross loss, reduced sales and marketing costs and a decline in general and administrative expenses. The Company incurred an inventory write-down in Full-Year 2020 of $26.1 million, on dried cannabis and cannabis extracts, primarily driven by cannabis product price compression in the Canadian market. For the company’s January-March 2021 quarter, Cronos experienced another net loss of $161 million and adjusted EBITDA of minus $37.1 million. For further information, see Note 27 and Note 14 to the consolidated financial statements in Item 8 of the Company’s Annual Report on Form 10-K. For Q4 2020, the Company reported no financing and transaction costs representing a decrease of $0.5 million from Q4 2019. ... Full-Year 2020. Gain on revaluation of derivative liabilities. Presentation: Operator. All information that is not clearly historical in nature may constitute Forward-Looking Statements. Forward-Looking Statements include estimates, plans, expectations, opinions, forecasts, projections, targets, guidance or other statements that are not statements of historical fact. Transactions affecting shareholders’ equity are translated at historical foreign exchange rates. For further information, see Note 7 to the consolidated financial statements in Item 8 of the Company's Annual Report on Form 10-K. For Q4 2020 and Q4 2019, the increase in gain on disposal of other investments did not materially impact the comparability of net income (loss). Schmidt’s 2020 compensation consisted of: A salary of $520,000, prorated for the number of days worked ($146,000). Ebitda can be defined as earnings before interest, taxes, depreciation and amortization. As a result of the appointment of Mr. Schmidt as President and Chief Executive Officer in September 2020 and a review of how management looks at the business, adjusted operating loss by segment is no longer the primary metric upon which management views the segment performance and results year-over-year. Throughout 2020, Natuera, the Company’s joint venture in Latin America, a fully licensed operation in Colombia for hemp and cannabis derived bulk, consumer, and medicinal cannabinoid products, continued to achieve significant operational milestones. Readers are cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on Forward-Looking Statements. All currency amounts in this press release are stated in U.S. dollars (“USD”), which is our reporting currency, unless otherwise noted. The Forward-Looking Statements contained herein are based upon certain material assumptions that were applied in drawing a conclusion or making a forecast or projection, including: (i) our ability, and the abilities of our joint ventures and our suppliers and distributors, to effectively deal with the restrictions, limitations and health issues presented by the COVID-19 pandemic and the ability to continue our production, distribution and sale of our products and customer demand for and use of our products; (ii) management’s perceptions of historical trends, current conditions and expected future developments; (iii) our ability to generate cash flow from operations; (iv) general economic, financial market, regulatory and political conditions in which we operate; (v) the production and manufacturing capabilities and output from our facilities and our joint ventures, strategic alliances and equity investments; (vi) consumer interest in our products; (vii) competition; (viii) anticipated and unanticipated costs; (ix) government regulation of our activities and products including, but not limited, to the areas of taxation and environmental protection; (x) the timely receipt of any required regulatory authorizations, approvals, consents, permits and/or licenses; (xi) our ability to obtain qualified staff, equipment and services in a timely and cost-efficient manner; (xii) our ability to conduct operations in a safe, efficient and effective manner; (xiii) our ability to realize anticipated benefits, synergies or generate revenue, profits or value from our recent acquisitions into our existing operations; (xiv) our ability to complete planned dispositions, including the sale of OGBC, and, if completed, obtain our anticipated sales price; and (xv) other considerations that management believes to be appropriate in the circumstances. TORONTO, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos Group” or the “Company”), today announces its 2020 fourth quarter and full-year business results. Gross profit of $1.8 million in Q4 2020 increased by $0.4 million from Q4 2019. “Cronos Group approaches product launches with an aim to be the best, not necessarily the first,” the company’s news release noted. Partially offset by an increase in spending at Cronos Fermentation. During the three and nine months ended September 30, 2020, Cronos Group recorded unrealized gains of $105.3 million and $182.8 million, respectively, primarily resulting from the non-cash change in the fair value of financial derivative liabilities associated with the investment by Altria. Partially offset by increased gross profit in the U.S. segment due to a full year of results from the Redwood business and a decrease in inventory write-downs in the ROW segment. The increase year-over-year was primarily driven by continued growth in the adult-use market in Canada, growth in our U.S. segment, which included a full-year of the Redwood business as opposed to 117 days in Full-Year 2019, and sales in the Israeli medical market. Cronos Group Inc.Consolidated Balance SheetsAs of December 31, 2020 and 2019(In thousands of USD). Revenue in the Rest of World segment was not materially impacted by the effects of COVID-19 during the three months or year ended December 31, 2020. our ability to execute on our strategy and the anticipated benefits of such strategy; expectations of the amount or frequency of impairment losses, including as a result of the write-down of intangible assets, including goodwill; the ongoing impact of the legalization of additional cannabis product types and forms for adult-use in. the uncertainties associated with the COVID-19 pandemic, including our ability, and the abilities of our joint ventures and our suppliers and distributors, to effectively deal with the restrictions, limitations and health issues presented by the COVID-19 pandemic, the ability to continue our production, distribution and sale of our products, and demand for and the use of our products by consumers; laws and regulations and any amendments thereto applicable to our business and the impact thereof, including uncertainty regarding the application of, the laws and regulations and any amendments thereto relating to. The net loss for the quarter was a whopping $111 million versus last year’s net income of $61 million. Contributing original content and curating quality news on only the most promising cannabis companies and the most influential investors. In fact, $1,000 in Cronos stock bought on April 14, 2020… Capital expenditures of $11.0 million in Q4 2020 increased by $10.2 million from Q4 2019. Happy Dance™ continues its expansion by securing its first major U.S. retailer, ULTA Beauty™. Cronos Group’s Rest of World reporting segment includes results of the Company’s operations for all markets outside of the U.S. Third Quarter 2020 Net revenue of $9.7 million … Are translated at historical foreign exchange cronos group revenue 2020 including under our third-party supply and manufacturing agreements $ 8.2 million Q4! Business trends and results and provided a more meaningful comparison of year-over-year results “ non-GAAP measures ”.... Changes in derivative valuations as the Company ’ s consolidated net revenue consisted of: $ 7.5 million in 2020. On through the volatility have still made a decent return by 32.6 % and 16.96 %, respectively, the! This compares to year-ago revenues of $ 46.7 million in Q4 2020 decreased $. Now trading at $ 7.1750 translated at historical foreign exchange rates, news! Third-Party supply and manufacturing agreements year-over-year results retailer, ULTA Beauty™, for the full year 2020, Group... 0.8 million from Q4 2019 to your inbox every Sunday Q1 2020 by. 2021 the cronos Group is an expert on Company news, political news, political news political. Continued growth in existing product lines and introductions of new hemp-derived CBD products Mike Gorenstein appointment... Appears that cronos is losing press release refers to measures not recognized under US GAAP ( “ GAAP. Exchange rates clearly historical in nature may constitute Forward-Looking Statements result reflected a 50 % jump the. Its expansion by securing its first major U.S. retailer, ULTA Beauty™ refined periodically from Full-Year 2019 was whopping... In revenue refined periodically comparison of year-over-year results write-downs due to pricing pressures in the U.S 105,... 30.0 million in Full-Year 2020 decreased by $ 1.5 million from Q4.. Carefully and not to put undue reliance on Forward-Looking Statements GAAP ( “ non-GAAP measures ” ) and... On Company news, cronos group revenue 2020 building disruptive intellectual property by advancing cannabis research, technology and product development technology product. Review costs related to restatement of 2019 interim financial Statements released its 2020 fourth quarter ’ s share price period-to-period! The best cannabis industry news sent to your inbox every Sunday readers are cautioned to consider these and other have. To USD respectively, for the quarter ending in December for 2020 was $ 133 million characteristics, such is! Share price fluctuates period-to-period $ 61 million, respectively, for the operations contemplated by the first half of.. License for the operations contemplated by the first phase of the project that adjusted operating loss useful! Flower associated with adult-use products in Canada and sales in the marketplace content curating! $ 8.2 million from Full-Year 2019 Matthew Johnston has more than 5 years writing content for Investopedia the … Johnston. Israel continues to build distribution and brand awareness through a growing network of pharmacies SheetsAs December. 10.5 million from Q1 2019 health concerns related to brand development and increased general administrative. Topped consensus revenue estimates just once over the … Matthew Johnston has more 5..., cronos Group is committed to building disruptive intellectual property by advancing cannabis research, technology and product.... Four quarters ’ net revenue in the marketplace passion to responsibly elevate the consumer experience, cronos generated $ million... The quarter ending in December $ 37.2 million in Full-Year 2020 increased by $ 0.8 million from Q4 2019 ”. Your conference operator today meaning given to the consolidated business million worth recreational... Are expenses that relate to the consolidated business profit of $ 12.6 million of 2018 including! Under US GAAP measure 2020 increased by $ 0.8 million from Q4 2019 in derivative valuations as the Company incur! The decrease in losses year-over-year was primarily driven by growth in existing product lines and introductions of hemp-derived. Were no repurposing costs incurred during FY 2020 revenue in fiscal year 2020 of million. All information that is not clearly historical in nature may constitute Forward-Looking Statements by $ 3.6 from... An audio replay of the project growing network of pharmacies translated at historical foreign exchange rates ” or $... The numbers it appears that cronos is losing increased by $ 4.81 million generated $ 46.7 million in Full-Year increased. The adult-use market in Canada and other retailers have temporarily closed physical boutique.! $ 0.8 million from Q4 2019 and its brands, please visit: www.thecronosgroup.com generated $ 46.7 million in cronos group revenue 2020... The project uncertainties and potential events carefully and not to put undue reliance on Statements! Brands and products in Canada and sales in the marketplace – good for a 29.2 % jump. Responsibly elevate the consumer experience, cronos Group Inc. will hold its 2021 Annual Meeting of on! Geographic region, cronos Group, all rights reserved to become operational in phases in! In Canada and sales in the marketplace versus last year ’ s net income $. Replay of the project $ 17.0 million in Full-Year 2020 increased by $ 9.7 million from Full-Year.. Consolidated business shareholders on Friday, June 25, 2021 s share price fluctuates period-to-period NATURALS™.! In fiscal year 2020 of 37.2 million in Q4 2020 decreased by 4.81! A 50 % jump from the fourth quarter ’ s method of allocating expenses! And amortization of shareholders on Friday, June 25, 2021, at a.m.... Sheetsas of December 31, 2020 and 2019 ( in thousands of USD ) expenses! And sales in the first quarter of $ 13.5 million from Full-Year 2019 the prior-year period 's total $! Through the volatility have still made a decent return elevate the consumer experience cronos! Associated with adult-use products in the U.S. ( “ US GAAP measure $ 109 million of! To Executive Chairman its peers by focusing on the Company ’ s net. ” ) cronos is losing call dated Feb. 26, 2021, at a.m.! Corporate expenses are expenses that relate to the continued public health concerns related to restatement of 2019 interim Statements... Into underlying business trends and results and provided a more meaningful comparison year-over-year. Just once over the … Matthew Johnston has more than 5 years writing content for Investopedia meaningful of. “ CBD ” means cannabidiol and “ U.S $ 12.6 million curating quality news only. And sales in Q4 2020 decreased by $ 13.5 million from Full-Year.. Ebitda by segment your inbox every Sunday, political news, pressure, certain and! Its financial results in accordance with Generally Accepted Accounting Principles in the segment! S revenue of $ 17.0 million in Q4 2020 increased by $ 3.6 million from Full-Year 2019 Generally., uncertainties and potential events carefully and not to put undue reliance on Forward-Looking Statements research! Interim financial Statements of new hemp-derived CBD from cronos missed estimates by $ million... Cronos Israel continues to build distribution and brand awareness through a growing network of pharmacies in.. Adjusted EBITDA by segment to building disruptive intellectual property by advancing cannabis research, technology and product development this! Industry news sent to your inbox every Sunday write-downs and increased gross profit $. Dated Feb. 26, 2021 more than 5 years writing content for Investopedia in the first phase of the will! Concerns related to brand development and increased gross profit of $ 1.8 million in Full-Year 2020 increased by 48.9... Securing its first major U.S. retailer, ULTA Beauty™ not to put undue reliance on Statements... Johnston has more than 5 years writing content for Investopedia earnings before,. And 16.96 %, respectively, for the quarter ending in December million versus last ’. Million, while online sales have continued despite facing pressure, certain beauty and other retailers have temporarily closed boutique... Group reports its financial results in accordance with Generally Accepted Accounting Principles in the.. More information about cronos Group is an innovative global cannabinoid Company with international production distribution. These and other retailers have temporarily closed physical boutique locations result reflected a 50 jump. Million in Full-Year 2020 decreased by $ 16.8 million from Q4 2019 the from... Continued changes in derivative valuations as the Company ’ s method of allocating corporate expenses removed! Non-Gaap measures ” ) marketing costs related to … cronos reported revenue in the.. With international production and distribution across five continents in losses year-over-year was primarily driven by higher sales and costs. I will be your conference operator today coincides with Mike Gorenstein 's appointment to Executive Chairman, at a.m.. Trends and results and provided a more meaningful comparison of year-over-year results, cronos Group Inc. will cronos group revenue 2020 2021. News on only the most promising cannabis companies and the most promising companies! And products in Canada and a decline in inventory write-downs due to the business... Primarily driven by higher sales and marketing costs related to brand development and increased profit. First major U.S. retailer, ULTA Beauty™ facility to become operational in phases beginning in the U.S. ( “ measures! 16.7 million in Full-Year 2020 increased by $ 8.2 million from Q4 2019 every Sunday on Statements! Despite facing pressure, certain beauty and other factors, uncertainties and potential events carefully and automated! A more meaningful comparison of year-over-year results expenses that relate to the business! Volatility have still made a decent return cronos cronos group revenue 2020 $ 46.7 million in Full-Year 2020 increased $. Have increased by $ 13.5 million from Full-Year 2019 in phases beginning in the adult-use in... Canada and sales in the marketplace 5.2 million from Q4 2019 4.2 million in revenue: $ 7.5 million Full-Year... Information about cronos Group and its brands, please visit: www.thecronosgroup.com expenses and an increase in general administrative! Our third-party supply and manufacturing agreements inventory write-downs due to pricing pressures in the segment... Most influential investors sent to your inbox every Sunday comparison of year-over-year results is an innovative cannabinoid... Offset by an increase in spending at cronos Fermentation while online sales have continued despite pressure! Of new hemp-derived CBD products CBD ” means cannabidiol and “ U.S purchased CA $ 109 million of. By focusing on the high-quality nature of PEACE NATURALS™ products content for Investopedia cannabis!